Home
NewsNewsThe EIB grants €20m to Overture Life to invest in automatization of assisted reproductive processes, scale product development, and support EU commercialization, including the DaVitri vitrification platform and non-invasive embryo assessment tools, under TechEU and InvestEU to improve IVF access and outcomes in Europe.
The European Investment Bank (EIB) grants €20m to Overture life to accelerate automatization of assisted reproductive processes, scale product development, and expand commercialization of IVF technologies in Europe, backed by the InvestEU programme and aligned with the EIB’s TechEU initiative.
The financing supports Overture Life’s R&D, manufacturing scale-up, and clinical trials to make IVF more effective and accessible, with a focus on automation and AI to improve pregnancy outcomes and reduce bottlenecks in fertility care across Europe. The agreement was signed during the Women Leaders in Life Science conference organized by the EIB Group at Bio-Europe in Vienna, highlighting policy momentum for reproductive-health innovation.
Overture Life develops automation for egg freezing and IVF procedures, aiming to reduce user variability and standardize complex steps that require specialized embryology skills, thereby increasing access for women. The company’s DaVitri vitrification platform is a compact tabletop device that automates vitrification preparation for mature oocytes and is designed to integrate into both new and existing embryology labs to expand throughput beyond high-capacity centers. The project also supports non-invasive metabolomics-based predictive tools to assess embryo implantation suitability, intended to enhance success rates and streamline decision-making in IVF.
The loan contributes to the EIB Group’s 2024–2027 Strategic Roadmap priority on digitalization and technological innovation, connecting directly to TechEU, which targets mobilization of €250 billion in innovation finance by 2027 for startups and scale-ups in the EU. The facility is guaranteed by InvestEU, the EU’s flagship program aiming to mobilize more than €372 billion in additional investment for EU policy goals from 2021 to 2027, reinforcing support for healthcare innovation and fertility infrastructure.
“We are delighted to join forces with research intensive startups like Overture to expand the range of healthcare and medical solutions available to European citizens. This new financing shows the EIB’s commitment to support technological innovation and the use of AI to develop breakthrough medical solutions,” said EIB vice president Karl Nehammer. “This new funding from our partners at EIB is more than just financial support,” said Hans Gangeskar, Overture Life’s CEO. “This is a signal that Europe understands the personal and demographic urgency of reproductive freedom. The EU has shown its willingness to make long-term public investments in fertility infrastructure and support new technologies, and we hope to see other jurisdictions follow the same path”.
By targeting automatization of assisted reproductive processes from egg freezing to embryo assessment, the financing addresses clinical workforce constraints and variability that affect IVF outcomes and capacity, potentially reducing time-to-treatment and improving standardization across clinics. If DaVitri and associated predictive tools achieve wider commercialization, Europe could see improved IVF access in secondary markets, with more consistent lab performance and reduced reliance on scarce embryology expertise. The transaction underscores the EIB’s use of venture-style instruments to catalyze medtech scale-up, positioning EU fertility tech within broader digital-health and AI priorities under TechEU and InvestEU.
As declining birth rates intensify focus on fertility access, the EIB grant €20m to Overture life financing sets a benchmark for public-backed investment into AI-enabled IVF infrastructure, with near-term milestones in R&D, trials, and European commercialization that could broaden access and improve outcomes in assisted reproduction.
Wisconsin lawmakers from both parties are proposing bills to reduce IVF treatment costs. Republicans suggest a $5,000 tax credit for expenses, while Democrats want mandatory insurance coverage. With IVF cycles costing $20,000-$30,000 and 170,000 residents facing infertility, both parties seek affordable solutions through different approaches.
The AI-specialized Infertility Center, which is the largest in Asia, is open in Magok, Seoul and has begun its full-scale medical services from November 17 thereby marking the new era when it comes to fertility in the region.
Alife Health secured CE Mark approval for its AI-powered embryo selection tool, Embryo Predict, under EU MDR, expanding its fertility technology presence across Europe.
Simbryo Technologies introduces the Simbryo FX personalized assay, a diagnostic test that measures endometrial fertility to predict embryo implantation success and improve IVF outcomes with more than 90% specificity.
South Korean couples travel abroad for gender-selective IVF procedures, spending dollars in Thailand and Cyprus due to domestic legal restrictions on choosing a baby's sex.
As more families pursue fertility treatments, IVF CRYO urges greater transparency and safety in better Safe Embryos and Eggs Shipping across the U.S.
China sees a rise in advanced maternal age In Vitro Fertilization, driven by BaseCare Medical’s AI undisturbed culture system that improves embryo quality and clinical pregnancy rates, especially with PGT. Localized AI-assisted solutions position BaseCare as a leader in smart, precision reproduction technology for older IVF patients.
